LIDDS AB develops pharmaceutical products for cancer and other diseases with NanoZolid technology. Its pipeline include NZ-Liproca Depot, NZ-DTX, NZ-DOX, NZ-IO, NZ-TLR9 and NZ-STING. The company was founded on November 4, 1999 and is headquartered in Uppsala, Sweden.